PDF(Pubmed)
Abstract：
Therapeutic and vaccine development for human poxvirus infections (e.g., monkeypox (mpox) virus, variola virus, molluscum contagiosum virus, orf virus) has been largely deserted, especially after the eradication of smallpox by 1980. Human mpox is a self-limited disease confined to Central and West Africa for decades. However, since April 2022, mpox has quickly emerged as a multi-country outbreak, urgently calling for effective antiviral agents and vaccines to control mpox. Here, this review highlights possible therapeutic options (e.g., tecovirimat, brincidofovir, cidofovir) and other strategies (e.g., vaccines, intravenous vaccinia immune globulin) for the management of human poxvirus infections worldwide.
摘要：
人类痘病毒感染的治疗和疫苗开发(例如，猴痘病毒,天花病毒,传染性软疣病毒,orf病毒)已经基本上被遗弃了，尤其是在1980年消灭天花之后.人类痘是一种自限性疾病，几十年来一直局限于中非和西非。然而,自2022年4月以来，水痘迅速成为多国疫情，紧急呼吁有效的抗病毒药物和疫苗来控制水痘。这里,这篇综述强调了可能的治疗选择(例如，tecovirimat,Brincidofovir,西多福韦)和其他策略(例如，疫苗,静脉注射牛痘免疫球蛋白），用于管理全球人类痘病毒感染。
